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AbstrACt
Introduction Mortality among children hospitalised for 
complicated severe acute malnutrition (SAM) remains high 
despite the implementation of WHO guidelines, particularly 
in settings of high HIV prevalence. Children continue to 
be at high risk of morbidity, mortality and relapse after 
discharge from hospital although long-term outcomes 
are not well documented. Better understanding the 
pathogenesis of SAM and the factors associated with poor 
outcomes may inform new therapeutic interventions.
Methods and analysis The Health Outcomes, 
Pathogenesis and Epidemiology of Severe Acute 
Malnutrition (HOPE-SAM) study is a longitudinal 
observational cohort that aims to evaluate the short-term 
and long-term clinical outcomes of HIV-positive and HIV-
negative children with complicated SAM, and to identify 
the risk factors at admission and discharge from hospital 
that independently predict poor outcomes. Children aged 
0–59 months hospitalised for SAM are being enrolled at 
three tertiary hospitals in Harare, Zimbabwe and Lusaka, 
Zambia. Longitudinal mortality, morbidity and nutritional 
data are being collected at admission, discharge and for 
48 weeks post discharge. Nested laboratory substudies 
are exploring the role of enteropathy, gut microbiota, 
metabolomics and cellular immune function in the 
pathogenesis of SAM using stool, urine and blood collected 
from participants and from well-nourished controls.
Ethics and dissemination The study is approved by 
the local and international institutional review boards 
in the participating countries (the Joint Research Ethics 
Committee of the University of Zimbabwe, Medical 
Research Council of Zimbabwe and University of Zambia 
Biomedical Research Ethics Committee) and the study 
sponsor (Queen Mary University of London). Caregivers 
provide written informed consent for each participant. 
Findings will be disseminated through peer-reviewed 
journals, conference presentations and to caregivers at 
face-to-face meetings.
IntroduCtIon
Malnutrition underlies almost half of all 
childhood deaths in developing coun-
tries.1 Severe acute malnutrition (SAM) 
is defined by a weight-for-height Z-score 
(WHZ) <–3, mid-upper arm circumference 
(MUAC) <115 mm and/or bilateral pitting 
strengths and limitations of this study
 ► Rigorous collection of longitudinal data on morbidity, 
mortality and nutritional status during inpatient care 
and for 48 weeks after initial admission for severe 
acute malnutrition (SAM) in HIV-positive and HIV-
negative children.
 ► Laboratory substudies investigating enteropathy, 
microbiota, metabolomics and immune cell func-
tion provide a unique opportunity to understand 
which pathogenic pathways contribute to SAM and 
whether these processes normalise with nutritional 
rehabilitation.
 ► High loss to follow-up due to participants returning 
to home settings following hospital discharge.
 ► The clinical heterogeneity of the study participants, 
including comorbidities such as infections, may 
make it challenging to identify the specific causes 
of clinical outcomes.
 ► Potential bias in recruiting well-nourished controls 
only from hospitals will be reduced by inclusion of 
community-based controls, including well-nour-
ished siblings of children with SAM.
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oedema.2 Current treatment guidelines distinguish two 
groups: (i) children with uncomplicated SAM who can 
be managed in the community and (ii) children with 
complicated SAM, who are hospitalised and undergo 
resuscitation, stabilisation and nutritional rehabilita-
tion. In-hospital mortality in children with complicated 
SAM remains high despite the implementation of WHO 
guidelines.3 Furthermore, SAM presents as two major 
clinical phenotypes: non-oedematous SAM (marasmus), 
characterised by severe wasting, and oedematous SAM 
(kwashiorkor), a more complex syndrome characterised 
by bilateral pitting oedema, steatosis and diarrhoea.4 5 
Despite differing clinical outcomes, treatment protocols 
are the same for both oedematous and non-oedematous 
SAM.
A contributory factor to high inpatient mortality is the 
co-occurrence of HIV infection in around one-third of chil-
dren hospitalised for SAM in sub-Saharan Africa.6 7 While 
new HIV infections in children have declined,8 a substan-
tial number of infected children are diagnosed late and 
present with malnutrition. There is also a growing popu-
lation of HIV-exposed uninfected (HEU) children who 
have immune abnormalities, poor growth and higher risk 
of mortality and infectious morbidity.9 Hence, HIV has 
transformed the epidemiology and outcomes of SAM.10 
Even with standardised treatment approaches, inpatient 
deaths are almost fourfold higher among HIV-positive 
children with SAM (herein termed HIV-SAM) compared 
with HIV-negative children with SAM (30.4% vs 8.4%), 
for reasons that remain unclear10; this mortality is three-
fold higher than would be expected from anthropometric 
parameters alone.10 Management of HIV-SAM is particu-
larly challenging because HIV fundamentally alters the 
clinical presentation of malnutrition and the response to 
treatment. Children with HIV-SAM are more stunted and 
wasted; have a higher frequency of persistent diarrhoea; 
tend to have delayed nutritional recovery and have a 
more complicated clinical course than HIV-negative chil-
dren with SAM.10
Long-term outcomes of sAM
Following resolution of complications and return of appe-
tite, children are discharged from hospital to continue 
therapeutic feeds at home. However, emerging data indi-
cate high post discharge mortality following in-hospital 
management of SAM.11–13 Malnutrition, together with 
young age, HIV infection and pneumonia, has been asso-
ciated with higher post discharge mortality.14 One of the 
largest prospective studies of growth and mortality in 
children with SAM (FuSAM), conducted in Malawi from 
July 2006 to March 2007, collected 12-month outcome 
data on 87% of 1024 children admitted to the nutrition 
ward.11 A total of 427 (42%) died and 44% of these deaths 
occurred after discharge from hospital. Survival was 
greatest among those who were nutritionally cured on 
discharge from outpatient therapeutic feeding centres, 
defined as two consecutive visits with >80% expected 
weight-for-height, no oedema and clinically stable. The 
risk of mortality after hospital discharge was fourfold 
higher for HIV-SAM compared with HIV-negative chil-
dren with SAM, but the outcomes among HEU children 
were not reported. The loss to follow-up was high in the 
FuSAM study because there was only one follow-up visit, 
1 year after discharge from outpatient-feeding centres. A 
recent study from Kenya identified malnutrition and HIV 
infection as key drivers for post discharge mortality, with 
52% of deaths attributable to MUAC <11.5 cm and 11% 
to HIV infection.15
The impact of SAM appears to persist beyond the first 
year after discharge from hospital. The ChroSAM study, 
which followed children with SAM 7 years post discharge, 
showed that children had poorer growth, body compo-
sition and physical function compared with siblings and 
community controls, which are all indicators of future 
cardiovascular and metabolic disease.12
While anthropometry is used to assess nutritional 
recovery after discharge from hospital, the pattern and 
quality of growth recovery following SAM is poorly under-
stood. The observation that children treated for SAM 
have a deficit in lean tissue despite regaining weight 
suggests that assessing body composition in addition to 
anthropometry may help to identify children who have 
not completely recovered and are at potential risk of 
long-term metabolic diseases.12 Children with HIV-SAM 
appear to have potential for catch-up growth in weight-
for-age and/or weight-for-height, which have been shown 
to normalise with treatment even prior to widespread 
availability of Antiretroviral Therapy (ART)16; by contrast, 
height-for-age shows less potential for catch-up growth.17 
However, the body composition of children with HIV-SAM 
compared with HIV-negative children with SAM has not 
been described. Whether children recover fat mass at 
the expense of lean mass is unknown, but differences 
in tissue accretion patterns may have implications for 
survival and long-term metabolic health.18 19 There is also 
a need to consider the effect of SAM on the size of body 
parts which grow at different rates: relatively shorter legs, 
for example, are associated with epidemiological risk of 
overweight, coronary artery disease, liver dysfunction and 
diabetes.20 21
Taken together, there is clearly an elevated risk 
of mortality among HIV-positive children with SAM 
compared with HIV-negative children with SAM, and an 
ongoing mortality risk among all children with SAM that 
persists after discharge from hospital. There are several 
gaps in our understanding of the long-term outcomes: 
(i) causes of death have not been clearly defined, (ii) no 
studies have systematically and longitudinally collected 
morbidity and mortality data or documented repeat 
hospitalisations post discharge and (iii) the long-term 
outcomes of HIV-positive children with SAM in the era of 
ART availability are unclear.
Pathogenesis of sAM
Better understanding the pathogenesis of SAM may help 
to explain the high mortality of children both during and 
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after hospitalisation and identify new targets for inter-
ventions to supplement existing treatment strategies. 
Consistent evidence that immune mediators are altered 
in malnutrition22 and that systemic and intestinal inflam-
mation are associated with poor outcomes in SAM23 
suggests that immune dysfunction contributes to infec-
tious susceptibility.24 Malnutrition is also characterised by 
a complex derangement in gut microbial,25 metabolic,26 
immune27 and hormonal pathways, organ dysfunction 
and micronutrient deficiencies in the context of co-in-
fections, enteropathy and chronic inflammation. Several 
studies have recently provided insights into these pertur-
bations using new tools,25 26 28 29 including metabolomics 
and metagenomics, but we still lack a clear understanding 
of many of the pathogenic pathways driving malnutrition, 
the interactions between these pathways and which are 
the most tractable targets for intervention.
SAM shares several pathological and clinical features 
with HIV, which may explain clinical outcomes in these 
co-occurring conditions: (i) both are characterised by 
intestinal damage, leading to impairment of the mucosal 
barrier and increased intestinal permeability; (ii) both 
have underlying systemic immune activation; and (iii) 
both are frequently complicated by persistent diarrhoea, 
pneumonia and sepsis that may plausibly arise due to 
loss of intestinal barrier function.30 Understanding the 
overlapping impact of HIV and SAM is critical to inform 
additional interventions to improve outcomes of children 
with HIV-SAM.
objECtIvEs of HoPE-sAM
The Health Outcomes, Pathogenesis and Epidemiology 
of Severe Acute Malnutrition (HOPE-SAM) study has two 
primary objectives:
1. To describe the short-term and long-term clinical out-
comes of children with complicated SAM, with and 
without HIV infection, and to identify the risk factors 
at admission and discharge from hospital that inde-
pendently predict these outcomes.
2. To better characterise the pathogenesis of SAM 
through nested laboratory substudies evaluating 
Figure 1 Study flow chart. All hospital admissions are screened for eligibility for the observational cohort and enteropathy 
substudy, with procedures undertaken as shown in the flow chart during hospitalisation and post discharge. Well-nourished 
children from outpatient clinics and the community meeting eligibility criteria as well-nourished controls are enrolled and 
undergo a single baseline assessment as shown. The immunology, microbiota and metabolomics substudies enrol children 
as shown. All children with severe acute malnutrition (SAM), regardless of which arm of the study they are enrolled into, are 
followed for 48 weeks post discharge. 1The immunology substudy started from 1 June 2017 and required children to have a 
blood sample >2 mL to conduct cellular assays. LM, lactulose-mannitol; WHZ, weight-for-height Z-score.
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enteropathy, gut microbiota, metabolomics and im-
mune cell function.
study dEsIgn
HOPE-SAM is a longitudinal observational cohort study, 
enrolling between 600–800 children aged 0–59 months 
admitted with complicated SAM to the tertiary paediatric 
wards at two sites in Zimbabwe (Parirenyatwa Hospital and 
Harare Children’s Hospital) and one in Zambia (Univer-
sity Teaching Hospital, Lusaka). Both HIV-positive and 
HIV-negative children will be enrolled. Throughout this 
paper, ‘SAM’ refers to all children, regardless of HIV 
status; where analyses specifically compare children by 
HIV status, groups are identified as HIV-positive chil-
dren with SAM (HIV-SAM) and HIV-negative children 
with SAM. All participants with SAM are followed for 48 
weeks post discharge, with longitudinal data collection 
and blood sampling. The study contains four nested 
substudies as shown in figure 1. A subgroup of children 
will be recruited to the enteropathy substudy for which 
they will have the same follow-up procedures but more 
intensive biological specimen collection including stool 
(all time points), urine after lactulose-mannitol (LM) 
challenge as an assessment of intestinal permeability 
and nasogastric aspirate (baseline only); these chil-
dren are also included in microbiota and metabolomics 
substudies. Children with SAM for whom blood samples 
are available are included in the immunology substudy, 
for which circulating inflammatory mediators will be 
assayed; functional cellular immunology assays will be 
conducted for all children in the immunology substudy 
with sufficient sample volume (>2 mL) recruited after 
June 2017. A group of healthy children recruited from 
the same hospitals and communities, who are well-nour-
ished and matched to children in the enteropathy 
substudy by age and HIV status, will have data and speci-
mens collected to provide normative data for the labora-
tory substudies; these well-nourished controls will not be 
followed longitudinally.
The study protocol, data collection forms and standard 




Caregivers of all hospitalised children are sensitised 
about the study. All new admissions aged 0–59 months 
are screened for SAM, which is defined according to 
WHO criteria as any of WHZ <–3, MUAC <115 mm (if 
aged 6–59 months) and/or bilateral pitting oedema. All 
children with SAM are recruited from hospital, and this 
study therefore focuses on complicated SAM; children 
with uncomplicated SAM will not be enrolled.
Eligibility for observational cohort
All children with SAM whose caregivers are willing to 
provide written informed consent and to learn their 
child’s HIV status are offered enrolment. Any children 
who die prior to study enrolment and those with a known 
malignancy are ineligible.
Eligibility for enteropathy substudy
Children with SAM aged 6–59 months with a nasogas-
tric tube in place (or due to be placed) are categorised 
into four groups (HIV-positive oedematous (group A -I); 
HIV-positive non-oedematous (group A-II); HIV-negative 
oedematous (group C-I) and HIV-negative non-oedema-
tous (group C-II)) as shown in table 1. Children meeting 
eligibility criteria will be enrolled throughout the study 
recruitment period until sufficient specimens have been 
collected from the groups shown in table 1. Children in 
the enteropathy substudy are stratified into age bands 
(6–11 months, 12–23 months and 24–59 months) to 
enable age-matching of well-nourished controls. Chil-
dren with underlying chronic gastrointestinal disease or a 
known malignancy are ineligible.
Eligibility for microbiota and metabolomics substudies
Children enrolled into the enteropathy substudy are also 
included in the microbiota and metabolomics substudies 
since these substudies use the stool, urine and plasma 
samples collected for enteropathy analyses.
Eligibility for immunology substudy
The immunology substudy comprises all children 
with SAM (drawn from both the observational cohort 
Table 1 Enteropathy substudy groups




















Note that children below 6 months of age are excluded from the enteropathy substudy to avoid interrupting exclusive breast feeding during 
the lactulose-mannitol test.
*SAM defined according to WHO criteria.
†Presence of bilateral pitting pedal oedema.
SAM, severe acute malnutrition; WHZ, weight-for-height Z-score.
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and the enteropathy substudy, as shown in figure 1) 
providing a blood sample of sufficient volume (>2 mL) 
for cellular assays after 1 June 2017.
Well-nourished controls
Controls are children drawn from the same hospi-
tals and communities as cases with SAM (including 
well-nourished sibling controls), who are aged 6–59 
months (matched to enteropathy substudy children 
within age bands), well-nourished (WHZ >–1) and 
clinically well (no acute illness or current infections) 
with known HIV status. Controls are categorised into 
two groups: well-nourished HIV-positive (group B) 
and well-nourished HIV-negative (group D), as shown 
in table 1. Children with underlying chronic gastro-
intestinal disease or a known malignancy are ineli-
gible. Well-nourished controls provide comparison 
biomarker data for all the laboratory substudies.
study ProCEdurEs
Study procedures are outlined in table 2.
Table 2 Summary of procedures in observational cohort
Assessment
Hospitalisation Post discharge*
Baseline† Discharge‡ 2 weeks 4 weeks 12 weeks 24 weeks 48 weeks





Acute admission information x
Baseline data x
Daily clinical review¶ Daily during hospitalisation
Blood collection** x x x x x
HIV testing†† x
CD4 count and viral load (HIV-infected 
children only)
x x x x
Full blood count‡‡ x x x x x
Anthropometry x x x x x x x
Skinfold thickness§§ x x x x x x
Body composition¶¶ x x x x x x x
Discharge data collection x
Daily morbidity diary Daily during follow-up period by caregivers
Follow-up clinic: history, examination, 
morbidity and mortality data
x x x x x
*Windows will be created around these post-discharge time-points to maximize follow-up for caregivers who miss visits or are unavailable, 
as follows: 2 weeks (optimal window from 1 week to 2 weeks + 6 days; allowable window up to 2 weeks + 6 days); 4 weeks (optimal window 
3-5 weeks, allowable window up to 9 weeks + 6 days); 12 weeks (optimal window 10-14 weeks, allowable window up to 19 weeks + 6 days); 
24 weeks (optimal window 20-28 weeks, allowable window up to 43 weeks + 6 days); 48 weeks (optimal window 44-52 weeks, allowable 
window up to 71 weeks + 6 days). †Children will be enrolled as soon as possible after hospitalisation and will undergo baseline investigations 
as soon as possible after enrolment. This is to provide a window of opportunity to time collection of research specimens with clinical 
specimens, and to ensure that the child is clinically stable before undertaking research investigations.
‡The discharge procedures will be undertaken on the day of discharge or as close as possible to that date.
§Locator information will be updated at subsequent visits if caregivers have moved or changed contact details.
¶A clinical review will be undertaken every day between admission and discharge by the study clinician.
**5.4 mL of blood (depending on child weight; amount will not exceed 2 mL/kg total over 2-week period) will be collected by a study nurse 
into endotoxin-free EDTA tubes. Samples will be used to store whole blood, Peripheral Blood Mononuclear Cells (PBMC) and plasma for 
subsequent measurement of C reactive protein and albumin. Where blood sample volumes allow (≥2 mL sample), bacterial binding assays 
and whole blood stimulations will be conducted and culture supernatants and cells stored for subsequent assessment of immune cell 
function at each time point. Study blood samples will not be collected from children with known haemoglobin <60g/L.
††HIV testing is conducted as part of routine clinical practice, but if it has not been undertaken, the study sample will be used to test for HIV, 
as stated in the informed consent form, since HIV status is required to allocate children to study groups.
‡‡Full blood count results will be transcribed from clinical records; if not done by clinical teams, the EDTA sample will be used to measure Full 
Blood Count (FBC) in clinical laboratories at each site.
§§Skinfold thickness (triceps, subscapular, supra-iliac) and mid-thigh circumference will be measured using Holtain callipers or tape measure.
¶¶Body composition will be assessed by bioimpedance vector analysis.
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baseline procedures
Baseline data on maternal and household characteris-
tics, the child’s medical history and current illness are 
collected by a study nurse. Anthropometry, including 
body composition measured by whole-body (wrist-ankle) 
bio-electrical impedance analysis (BodyStat 1500MD; 
BodyStat, UK), leg length using an electronic knemom-
eter (Zimbabwe only, due to availability of knemometers) 
and triceps, subscapular and supra-iliac skinfold thickness 
using callipers (Holtain, Crymych, UK), are undertaken 
at baseline. Blood (1 mL/kg up to 5.4 mL maximum) is 
collected at baseline into an endotoxin-free EDTA tube 
for all children and, in the enteropathy substudy, addi-
tionally into a PAXgene tube (PreAnalytiX, Hombrech-
tikon, Switzerland) for subsequent transcriptomic 
analysis. Blood is not collected from children with severe 
anaemia (known haemoglobin <60 g/L). HIV testing is 
carried out in accordance with national guidelines as part 
of routine clinical practice; where it has not been done, 
the child’s HIV status is ascertained using a rapid test 
antibody algorithm for children over 18 months, or HIV 
DNA PCR for children under 18 months. CD4 count/
percentage and viral load are measured in HIV-positive 
children. Maternal HIV status is documented where avail-
able, so that HIV-exposed uninfected children can be 
identified. Blood samples are sent to research laborato-
ries at each site to conduct whole blood stimulation and 
bacterial binding assays (as described in the immunology 
substudy) and to store aliquots of whole blood, periph-
eral blood cells and plasma at −80⁰C.31 In the enteropathy 
substudy, nasogastric aspirate, stool and urine (after an 
oral dose of lactulose and mannitol) are also collected. 
Lactulose and mannitol are ingested by the child after 
fasting and urine is collected over a 2-hour period to 
measure recovery of lactulose and mannitol, a measure of 
intestinal absorptive capacity and permeability, as previ-
ously described.32
daily procedures
Routine inpatient management is undertaken by ward 
clinical teams according to local hospital protocols, 
which are based on WHO guidelines.2 33 In addition, 
the HOPE-SAM study clinician at each hospital site 
collects daily data until discharge on clinical param-
eters (including daily examination), resolution of 
acute infections, nutritional recovery (loss of oedema, 
restoration of appetite, weight gain) and treatment/
nutritional supplements received; this will allow us to 
evaluate differences in management between coun-
tries. Children with HIV-SAM who are ART-naive 
start ART according to national guidelines, which are 
based on WHO recommendations.2 34
discharge
The clinical team decides when the child is ready to 
be discharged, which is generally when their medical 
complications are resolving and the child has a good 
appetite and is clinically well and alert.2 Children receive 
ready-to-use therapeutic feeds (RUTF) to take at home 
according to local guidelines. At discharge, the study 
nurse collects data and a repeat blood sample (including 
full blood count) and undertakes discharge anthropom-
etry, body composition, leg length (Zimbabwe only) and 
triceps, subscapular and supra-iliac skinfold thickness 
measurements (table 2). The caregiver is given a daily 
morbidity diary and pre-prepared stickers corresponding 
to different illnesses and shown how to complete the 
diary. The caregiver is provided with the date of the first 
follow-up appointment and contact details of the study 
nurse.
follow-up
Children attend follow-up appointments at dedicated 
study clinics at 2, 4, 12, 24 and 48 weeks post discharge. 
At each visit, the study physician undertakes a clinical 
assessment and the study nurse captures illness, medica-
tion and feeding data. Clinic data are transcribed from 
handheld medical records if available and the morbidity 
diary is reviewed and a new diary and stickers supplied. 
Anthropometry, body composition, leg length (Zimbabwe 
only) and triceps, subscapular and supra-iliac skinfold 
thicknesses are measured at each visit. Acute illnesses 
are treated in the study clinic or the child is referred to 
hospital if necessary. Children with relapsed malnutri-
tion are provided with nutritional supplements or RUTF 
according to local guidelines or readmitted to hospital 
if they develop complicated SAM. Transport reimburse-
ment for clinic attendance is provided to caregivers for 
each visit.
Blood is collected at weeks 12, 24 and 48 
post discharge into endotoxin-free EDTA tubes to 
measure full blood count, CD4 count and viral load 
(HIV-positive children only), conduct whole blood 
stimulation and bacterial binding assays (where 
blood volumes > 2 mL) and store peripheral blood 
cells and plasma aliquots for subsequent analyses 
(all blood samples), including soluble and cellular 
markers of immune activation, as outlined in online 
supplementary table 1. Children in the enteropathy 
substudy have additional stool and urine collection 
following lactulose-mannitol dosing as shown in 
table 3.
Caregivers are reminded of follow-up visits by phone, 
and visit completion is tracked on a dedicated database. 
If caregivers do not attend follow-up appointments, 
attempts are made to contact them by phone and home 
visits are made if feasible, particularly for those defaulting 
on the 48-week visit, so that long-term outcome data can 
be collected. For post discharge deaths, a home visit is 
undertaken by study nurses where possible to conduct a 
verbal autopsy. Children who are readmitted to one of the 
study sites with relapsed SAM have data collected during 
the new episode of hospitalisation. The study ends for 
each participant at the week 48 visit.
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substudIEs
As outlined in figure 1, four nested substudies will use 
biological specimens to address mechanistic questions 
related to enteropathy, microbiota, metabolomics and 
immune function.
Enteropathy substudy
The gut, which acts as an internal interface between 
humans and the environment, must contain the nutrient 
stream and the symbiotic microbiota while allowing 
molecular intimacy to permit absorption. The mechanism 
underlying this duality is the integrity of the gastrointes-
tinal barrier; intestinal damage (enteropathy) can impair 
this critical barrier function. A spectrum of enteropathies 
affect children in developing countries.30 Environmental 
enteric dysfunction (EED), characterised by small intes-
tinal inflammation, blunted villi and increased intestinal 
permeability, is almost universal and is morphologically 
indistinguishable from HIV enteropathy.30 Children in 
Table 3 Summary of procedures for cases in the enteropathy substudy
Assessment
Hospitalisation Post discharge*
Baseline† Discharge‡ 2 weeks 4 weeks 12 weeks 24 weeks 48 weeks
Caregiver informed consent to join observational 




Acute admission information X
Baseline data X
Daily clinical review¶ Daily during hospitalisation
Blood collection** X X X X X
HIV testing†† X
CD4 count and viral load (HIV-infected children 
only)
X X X X
Full blood count‡‡ X X X X X
Gastric aspirate§§ X
Stool collection¶¶ X X X X X
Lactulose-mannitol testing*** X X X X
Anthropometry X X X X X X X
Skinfold thickness††† X X X X X X
Body composition‡‡‡ X X X X X X X
Discharge data collection X
Daily morbidity diary Daily during follow-up period by caregivers
Follow-up clinic: history, examination, morbidity 
and mortality data
X X X X
*Windows will be created around these post-discharge time points to maximise follow-up for caregivers who miss visits or are unavailable, as follows: 2 
weeks (1–3 weeks); 4 weeks (3–5 weeks); 12 weeks (10–14 weeks); 24 weeks (20–28 weeks) and 48 weeks (44–52 weeks).
†Children will be enrolled within 24 hours of hospitalisation and will undergo baseline investigations within 72 hours of hospitalisation. This is to provide 
a window of opportunity to time collection of research specimens with clinical specimens, and to ensure that the child is clinically stable before 
undertaking research investigations.
‡The discharge procedures will be undertaken on the day of discharge or as close as possible to that date.
§Locator information will updated at subsequent visits if caregivers have moved or changed contact details.
¶Daily clinical review will be conducted every day between admission and discharge by the study clinician.
**During hospitalisation, 5.4 mL of blood (depending on child weight; amount will not exceed 2 mL/kg total over 2-week period) will be collected by 
a study nurse into a 2.7 mL endotoxin-free EDTA tube and a 2.7 mL PAXGene tube, for subsequent isolation of RNA and gene expression analysis. 
After discharge (weeks 12, 24 and 48), 5.4 mL of blood (depending on child weight; amount will not exceed 2 mL/kg total over 2-week period) will be 
collected by a study nurse into two 2.7 mL endotoxin-free EDTA tubes.
††HIV testing is conducted as part of routine clinical practice, but if it has not been undertaken, the study sample will be used to test for HIV (see 
section 9.4), as stated in the informed consent form, since HIV status is required to allocate children to study groups.
‡‡Full blood count results will be transcribed from clinical records; if not done by clinical teams, the EDTA sample will be used to measure FBC in 
clinical laboratories at each site.
§§A gastric juice sample will be collected at the same time as the blood draw by aspirating the nasogastric tube with a sterile feeding syringe, to test 
for gastric pH; sterile water or saline will then be instilled and a sample of gastric juice collected for storage for subsequent PCR and culture (section 
7.5.2).
¶¶Stool collection will be undertaken at the same time as the blood draw.
***Lactulose-mannitol (LM) testing will be conducted, with collection of a baseline urine sample, followed by a 2-hour urine collection post-LM 
ingestion. This test will be deferred until children are judged to be clinically stable by the study physician during daily reviews. In general, this will be a 
child in the nutritional rehabilitation phase, who has no cardiorespiratory compromise.
†††Skinfold thickness (triceps, subscapular, supra-iliac) and mid-thigh circumference will be measured using Holtain callipers or tape measure.
‡‡‡Body composition will be assessed by bioimpedance vector analysis.
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resource-poor settings also suffer from frequent diar-
rhoea, food insecurity and micronutrient deficiencies, 
which all exacerbate enteropathy.30 As a result, a cycle 
of intestinal infection, impaired mucosal function and 
malnutrition commonly arises, which may ultimately 
precipitate SAM, especially in the context of HIV infec-
tion.35 36 It is not yet established if the enteropathy seen 
in children with SAM,37 which we here refer to as malnu-
trition enteropathy,37 is qualitatively or quantitatively 
distinguishable from EED. In addition to local intestinal 
pathology, enteropathies may cause systemic pathology 
due to persistent immune activation arising from enteric 
inflammation and microbial translocation across the 
damaged gut wall.30 It is becoming apparent that chronic 
inflammation may be particularly deleterious in malnour-
ished individuals23; in children with SAM, systemic inflam-
mation arising from underlying enteropathy may further 
increase morbidity and mortality.
We hypothesise that (i) the degree of enteropathy 
during hospitalisation differs between oedematous and 
non-oedematous SAM and is independently associated 
with morbidity, mortality and nutritional recovery during 
hospitalisation; (ii) the degree of enteropathy at discharge 
is independently associated with morbidity, mortality and 
relapse of SAM; and (iii) children with HIV-SAM have 
more severe enteropathy than HIV-negative children with 
SAM, which contributes to their poorer outcomes.
Using stored samples, a longitudinal series of investiga-
tions will compare gastric and small intestinal barrier func-
tion, using a range of biomarkers to capture the domains 
of malnutrition enteropathy (online supplementary 
table 2). To understand better the extra-intestinal conse-
quences of enteropathy, we will first compare the micro-
bial composition of the upper gut and plasma using deep 
sequencing in a subgroup of children with paired gastric 
and blood samples. Second, we will undertake transcrip-
tomics using PAXGene blood samples to determine (i) 
whether there are differences in gene expression profiles 
between well-nourished controls, HIV-negative children 
with SAM and HIV-positive children with SAM (including 
comparison of oedematous and non-oedematous types); 
and (ii) whether specific patterns of gene expression are 
associated with morbidity and mortality in SAM.
Microbiota substudy
Normal assembly of the gut microbiota in early life is crit-
ical for many aspects of physiological, neurological and 
immune development.38 Recent evidence suggests that an 
immature or pathogenic microbiota plays a causative role 
in the pathogenesis of SAM.25 For example, a number 
of microbial taxa have been identified, including Faecal-
ibacterium prausnitzii, which discriminate and predict gut 
microbiota maturity and child growth.28 Other pathogenic 
microorganisms, including IgA-targeted Enterobacteriaceae, 
are associated with impaired growth and may contribute 
to SAM.39 Nutritional rehabilitation with RUTF induces 
temporary recovery of a disturbed microbiota; however, 
the microbiota appears to revert back to an immature 
diseased state following nutritional recovery.29 HIV infec-
tion is also associated with a disturbed gut microbiota,40 
which may further compound enteropathy phenotypes. 
Furthermore, there is some evidence that differences 
exist in malnutrition enteropathy between oedematous 
and non-oedematous SAM41; however, few studies have 
investigated differences in the gut microbiota between 
the two forms of the disease.
We hypothesise that (i) a unique gut microbial signa-
ture exists in HIV-SAM, compared with HIV-negative 
children with SAM, that is independently associated with 
morbidity, mortality, nutritional recovery and degree of 
enteropathy during hospitalisation; (ii) a unique gut 
microbial signature exists in oedematous compared with 
non-oedematous SAM; (iii) specific microorganisms or 
gut microbial diversity indices are independently associ-
ated with morbidity, mortality, nutritional recovery and 
degree of enteropathy during hospitalisation; and (iv) the 
gut microbiota is partially restored to a healthy state with 
nutritional rehabilitation but reverts to a dysbiotic state 
during follow-up, which predicts morbidity, mortality and 
relapse of SAM.
Using stored stool samples collected at baseline, a 
cross-sectional investigation will determine differences 
in the gut microbial composition and predicted func-
tion between: HIV-negative children with SAM versus 
HIV-SAM, oedematous versus non-oedematous SAM and 
well-nourished controls. Gut microbial composition and 
predicted function will be compared between groups 
at discharge and at 12, 24 and 48 weeks post discharge. 
Briefly, total DNA and/or RNA will be extracted from 
stool samples and used as template for next-generation 
sequencing library preparation and for quantitative 
PCR. Whole metagenome shotgun sequencing will be 
performed using the HiSeq 2500 system. Raw metage-
nomic sequencing data will be quality-filtered and anal-
ysed through a well-validated bioinformatics pipeline 
using MetaPhlAn42 and HUMAnN.43 The compositional 
and predicted functional metagenomic data generated 
will be used to identify signatures of SAM and to investi-
gate associative links between specific gut microbial signa-
tures and clinical outcomes.
Metabolomics substudy
During SAM, metabolic processes are altered in response 
to a starved environment and may plausibly contribute 
to long-term clinical outcomes. Previous studies suggest 
that amino acid turnover, lipid metabolism, oxidative 
stress and other metabolic pathways are disrupted in 
SAM and may be associated with disease state and clin-
ical outcome26 44 45; however, little is known about how 
the metabolic phenotype responds to nutritional therapy. 
It is hypothesised that disturbed gut microbiota compo-
sition and function may drive microbial metabolic 
dysregulation in addition to host-derived dysregulation. 
Of particular interest are differences in the metabolic 
phenotype between oedematous and non-oedematous 
SAM. The ‘reductive adaptation’ seen in non-oedematous 
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SAM (utilisation of fat and muscle stores) is disrupted in 
oedematous SAM, which may contribute to differences in 
clinical outcomes. Specifically, protein turnover, inflam-
mation, oxidative stress and bile acid metabolism are 
disrupted in oedematous-SAM, which may contribute to 
comorbidities including diarrhoea, steatosis and enterop-
athy.46 47
We hypothesise that (i) a unique plasma and urine 
metabolic phenotype exists in oedematous compared 
with non-oedematous SAM during hospitalisation, which 
is independently associated with morbidity, mortality 
and nutritional recovery; (ii) the metabolic phenotype is 
partially restored to a healthy state with nutritional reha-
bilitation but reverts to a disturbed state during follow-up, 
which predicts morbidity, mortality and relapse; and (iii) 
both host-derived and gut microbial-driven metabolic 
dysregulation underlie clinical outcomes.
Using stored urine and plasma samples collected 
during hospitalisation, a cross-sectional investigation 
will determine differences in the metabolic phenotype 
between children with oedematous SAM, non-oedema-
tous SAM and well-nourished controls. Urine and plasma 
metabolic phenotypes will be compared between groups 
at discharge and 12, 24 and 48 weeks post discharge. 
Briefly, global untargeted metabolomic phenotyping will 
be performed via 1H nuclear magnetic resonance (NMR) 
spectroscopy using a 700 MHz Bruker NMR spectrometer 
to identify metabolic signatures of SAM. Targeted anal-
ysis via ultra-performance liquid chromatography-mass 
spectrometry will be performed to examine specific 
pathways of interest, including tryptophan and bile acid 
metabolism.
Immunology substudy
Bacterial infections are common among children hospi-
talised for SAM23 48–50 and mortality is driven by a range 
of species,48 50–53 consistent with generalised defects 
in innate antibacterial defence. Increased infectious 
morbidity and mortality persist after discharge from 
hospital,10 17 54 suggesting that restoration of antibacte-
rial immune responses may lag behind nutritional reha-
bilitation. A recent randomised trial in children with 
SAM confirmed that deaths following hospitalisation 
were predominantly due to bacterial infections but were 
not prevented by daily co-trimoxazole prophylaxis.17 
Collectively, these observations highlight that children 
remain vulnerable to infection despite current treat-
ment approaches; targeting persistent immune dysfunc-
tion could plausibly reduce infectious mortality after 
discharge.24
Multiple innate and adaptive immune mediators are 
dysregulated in malnutrition.24 27 55 However, few studies 
have assessed cellular immune function in malnourished 
children; most existing studies were undertaken decades 
ago on small cross-sectional cohorts without the benefit 
of recent advances in immunology techniques.27 Immune 
dysfunction in SAM likely reflects both intrinsic defects, 
whereby immune cells lack capacity to adequately respond 
to infection, and extrinsic defects, where cells have intact 
antibacterial capacity but are chronically modulated by 
the systemic pro-inflammatory environment which char-
acterises SAM (ie, heightened pro-inflammatory cyto-
kines44 and circulating bacterial antigens23 56 57). Systemic 
inflammation is directly associated with mortality in 
SAM23 and driven by multiple comorbidities, including 
bacterial translocation from the damaged gut into the 
blood, subclinical infections and metabolic dysregu-
lation.44 58 59 The implications of innate immune cell 
dysfunction for subsequent acquisition of infections and 
infectious mortality have not been investigated.
We hypothesise that (i) antibacterial functions of innate 
immune cells are compromised in SAM due to a combina-
tion of intrinsic and extrinsic defects; (ii) innate immune 
cell function is independently associated with infectious 
morbidity and mortality during hospitalisation for SAM; 
and (iii) nutritional rehabilitation only partly restores 
innate immune cell function, leading to an ongoing risk 
of bacterial infections post discharge.
Using blood samples collected at baseline, discharge 
and 12, 24 and 48 weeks post discharge, the longitudinal 
relationship between circulating innate immune cell 
function and bacterial infections will be assessed. The 
intrinsic phagocytic capacity, secreted cytokine response 
and maturation state of innate immune cells after culture 
with bacterial antigens will be assessed. Plasma concentra-
tions of endotoxin and pro-inflammatory mediators will 
be quantified at each time point and the degree to which 
these extrinsic factors influence innate immune cell anti-
bacterial function will be assessed via plasma co-culture 
with innate immune cells from healthy donors. Bacte-
rial infections during hospitalisation will be diagnosed 




The observational cohort will recruit as many children 
with SAM as possible during the period of enrolment 
(July 2016 to March 2018), estimated at 600–800 children 
(capped at 800 maximum), to assess clinical and nutri-
tional outcomes among HIV-positive and HIV-negative 
children hospitalised with SAM. Assuming mortality of 
15%, overall loss to follow-up of 15% and recruitment 
target of 800 children, there would be 560 evaluable 
children at 48 weeks, of whom 224 would have HIV-SAM 
based on an estimated inpatient HIV prevalence of 40%. 
This will provide >80% power to detect absolute differ-
ences of 17% in binary outcomes between HIV-SAM and 
HIV-negative children with SAM, and of 0.33 times the SD 
in continuous outcomes.
Enteropathy substudy
The sample size was estimated using previously reported 
values for LM ratios, which remain a widely used 
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non-invasive marker of enteropathy. Comparing 100 
versus 100 children with two-sided alpha=0.025 (to allow 
for two primary comparisons, ie, HIV-SAM vs HIV-nega-
tive children with SAM, and HIV-SAM vs well-nourished 
HIV-positive children) provides >80% power to detect 
differences in mean LM ratio during hospitalisation of at 
least 0.16 (assuming SD 0.36), a difference which would be 
clinically relevant given the LM ratios previously reported 
for well-nourished children (0.42), malnourished chil-
dren (1.3) and children with persistent diarrhoea (2.85) 
in the Gambia.60 It also provides >80% power to detect 
differences of at least 0.1 in the mean change in LM ratio 
from enrolment (assuming SD for change=0.23 and 7% 
missing samples). For inflammatory markers, comparing 
100 versus 100 children with two-sided alpha=0.025 
provides >80% power to detect differences in mean log10 
concentrations of at least 0.44 times their SD, or 2.75-
fold differences between groups. Inclusion of well-nour-
ished controls provides an indication of normal ranges 
in young African children. HIV-positive and HIV-negative 
SAM groups will be stratified to include approximately 50 
children with and without oedematous malnutrition, if 
possible.
Microbiota and metabolomics substudy
Power calculations are difficult in metagenomics and 
metabolomic analyses due to the large number of observed 
outcomes and unknown effect sizes and variance. Previous 
studies using smaller sample sizes have identified signifi-
cant taxonomic differences in twin pairs discordant for 
oedematous-SAM (n=13)25 and metabolic differences 
between the two forms of SAM (n=40).26 These studies 
suggest that a difference of 50% in metabolites could be 
expected. Using analysis of covariance, setting α=0.05 and 
assuming either low (ρ=0.1) or high (ρ=0.7) correlation, 
the study would require 95–126 subjects to achieve 80% 
power.61 False discovery rate multiple correction testing 
will be applied to reduce the high-dimensionality of the 
data and limit false positives.
Immunology substudy
Up to 200 children with SAM and 200 well-nourished 
controls will be included in a cross-sectional analysis of 
innate immune cell function during hospitalisation. 
Assuming similar infectious mortality to a recent Kenyan 
study (15%),17 a cohort of 200 provides 80% power to 
detect associations between immune profiles and infec-
tious mortality at an OR of 1.7 and two-sided alpha of 
0.05. We will aim for 100 children with longitudinal anal-
ysis of innate immune cell function at discharge, 12, 24 
and 48 weeks post discharge.17
study outCoMEs And rIsk fACtors
The main study outcomes are clinical (mortality, 
morbidity and relapse of malnutrition) and nutri-
tional (weight, height, MUAC, leg length, head 
circumference, mid-thigh circumference, skin-fold 
thickness and body composition by bioimpedance 
vector analysis) assessed over 48 weeks of follow-up. 
Mortality is assessed in hospital by daily physician 
review and, post discharge, through study visits and by 
telephone where possible for children who are lost to 
follow-up. Morbidity during hospitalisation is assessed 
through daily clinical assessments and available 
hospital laboratory tests. Morbidity after discharge is 
assessed, first, using daily morbidity diaries, in which 
caregivers record episodes of illness (lethargy inter-
fering with feeding; respiratory distress; diarrhoea; 
oedema and fever); second, from caregiver recall and 
review of handheld medical records at each follow-up 
visit; and, third, from data collected during hospital-
isation for children who are readmitted during the 
follow-up period. Time-to-recovery from malnutri-
tion will be evaluated during hospitalisation; relapse 
of malnutrition during follow-up will be categorised 
as moderate acute malnutrition, uncomplicated 
SAM and complicated SAM, according to WHO 
definitions. Nutritional outcomes will be expressed 
both as continuous variables (attained Z-score and 
change in Z-score between visits), and as categor-
ical variables (moderate wasting, WHZ<–2; severe 
wasting, WHZ<–3; stunting, HAZ<–2; severe stunting, 
HAZ<–3; underweight, WAZ <–2; and microcephaly, 
head circumference-for-age <–2).
Risk factors will be evaluated at baseline, hospital 
discharge and over the period of follow-up for associ-
ations with clinical and nutritional outcomes. In addi-
tion to baseline clinical and demographic factors, the 
following laboratory parameters will be evaluated: 
haemoglobin, serum albumin, C reactive protein (CRP), 
CD4 count and HIV viral load (for HIV-positive chil-
dren). Haemoglobin, CD4 and HIV-viral load will be 
measured in real time and the results reviewed during 
follow-up clinics.
Data on potential confounders are collected at baseline, 
discharge and during the follow-up period, including 
child feeding practices, household socioeconomic status 
(defined by household income and cooking method), 
maternal employment and education, and household 
factors such as water, sanitation and hygiene practices, 
availability of electricity, location (rural, peri-urban or 
urban) and household size.
AnALysIs
All analyses will be interpreted exploratively since 
HOPE-SAM is an observational study with multiple risk 
factors, outcomes and substudies. For all analyses, p 
values will not be artificially adjusted, but interpreted as 
exploring the strength of evidence supporting any asso-
ciation. The only exception is the use of approaches to 
minimise false discovery when analysing high-dimen-
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observational cohort
The primary comparison will be the clinical and nutri-
tional outcomes of children with HIV-SAM compared 
with HIV-negative children with SAM. We will review all 
deaths and adjudicate clinical diagnoses and causes of 
death to ensure robust and consistent data across sites. 
We will compare each participant’s clinical management 
to WHO guidelines to identify any contributory factors 
in hospital care. Factors associated with outcomes during 
hospitalisation (eg, mortality, nutritional recovery) will 
be determined for each group (HIV-SAM and HIV-nega-
tive children with SAM) using multivariable analysis (Cox 
models for time-to-event data, linear models for contin-
uous outcomes). Factors associated with outcomes over 
48 weeks post discharge (hospital readmission, morbidity 
and mortality, relapse, anthropometry, body composition 
and response to ART) will be determined for each group 
(HIV-SAM and HIV-negative children with SAM) using 
multivariable analysis (Cox models for time-to-event 
data, linear models for continuous outcomes). HIV-pos-
itive children with SAM and HIV-negative children with 
SAM will be included in one model together with the risk 
factors, and interaction tests will be used to investigate 
whether associations between risk factors and outcomes 
differ between the two groups of children. We will eval-
uate the ability of MUAC at discharge to predict long-term 
outcomes using receiver-operator-characteristic (ROC) 
analysis, in the whole cohort and within the subgroups 
of HIV-SAM and HIV-negative children with SAM. We 
will then evaluate whether addition of other variables 
improves the predictive capacity of MUAC (using WHO 
criteria in those >6 months, and published data for chil-
dren <6 months62) for each group, including body compo-
sition, haemoglobin, albumin and CRP, plus CD4%, viral 
load and timing of ART initiation (HIV-SAM only). We 
will construct multivariable models and compare them 
with MUAC alone using the net-reclassification index.
body composition analysis
Previous work in body composition by bio-electrical 
impedance in Ethiopian infants and children with SAM 
has shown that the conventional approach, predicting 
total bodyweight from height-adjusted impedance, fails 
due to confounding by oedema.63 The same project 
validated an alternative approach, known as Bio-elec-
trical Impedance Vector Analysis, and described signifi-
cant differences between each of three groups: healthy 
controls, oedematous-SAM and non-oedematous SAM. 
Vector analysis splits impedance into two height-adjusted 
components, resistance and reactance, which are further 
linked through phase angle (PA). Variability in these 
components is associated with biochemical parameters.64 
These variables will be explored using graphical anal-
ysis or transformed into age-adjusted and sex-adjusted 
Z-scores for statistical comparison, including longitudinal 
analyses. Higher PA indicates better nutritional status, 
while declining height-adjusted resistance over time indi-
cates loss of oedema.
Enteropathy substudy
The primary comparison for the enteropathy substudy 
will be between HIV-positive children with SAM (group 
A) and HIV-negative children with SAM (group C), strat-
ified by presence or absence of oedema. Control groups 
(B and D) are well-nourished children with or without 
HIV, to provide normative data for biomarkers and 
to evaluate the impact of SAM within each HIV group. 
Thus, biomarkers among HIV-positive children with 
SAM will first be compared with HIV-negative children 
with SAM (to evaluate the impact of HIV) and, second, 
with well-nourished HIV-positive children (to evaluate 
the impact of SAM). Biomarkers among HIV-negative 
children with SAM will be compared with well-nourished 
HIV-negative children. For each continuous outcome, 
simple descriptive analysis will be used to compare 
groups during hospitalisation using t-tests on appropri-
ately transformed data. For any outcome with moderate 
(p<0.05), evidence of difference between either group a 
regression model will be constructed including groups A, 
B, C and D to directly test (using interactions) whether 
there is a synergistic effect of HIV-SAM versus HIV-nega-
tive SAM versus HIV alone versus neither. These models 
will also be used to explore whether there is any evidence 
for heterogeneity in effects between oedematous and 
non-oedematous SAM. Associations between enrolment 
factors (eg, intestinal permeability and microbial translo-
cation) will be explored using pairwise Spearman correla-
tions and principal components analysis. Mean changes 
at the follow-up time points in each group will be esti-
mated, and groups compared (as above) using gener-
alised estimating equations. For outcomes that differ 
across SAM groups over time, multilevel models will be 
used to explore possible predictors from the other factors 
measured. Time to nutritional recovery will be compared 
using Kaplan-Meier and log-rank tests, and Cox models to 
adjust for baseline differences between groups.
Microbiota and metabolomics substudy
The primary comparison will be between HIV-negative 
children with oedematous and non-oedematous SAM, 
with a separate comparison between HIV-positive children 
with SAM and HIV-negative children with SAM. Analyses 
will examine (i) differences in metagenomic/metabo-
lomic variables between groups at each time point; (ii) 
differences in metagenomic/metabolomic variables 
within groups over time; (iii) correlations between metag-
enomic and metabolomic variables and (iv) correlations 
between metagenomic/metabolomic variables and clin-
ical outcomes. A systematic analysis will be undertaken to 
reduce high-dimensional data, integrate the multi-omics 
data sets and minimise false discovery.
Compositional metagenomic data will be compared 
between groups for indices of alpha and beta diversity. 
Principal coordinate analysis and partial least-squares 
discriminant analysis will be performed on metabolo-
mics data to identify overall differences between groups. 
High-dimensional data sets will be reduced using random 
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forest models to identify taxa, microbial gene families 
and metabolites that most strongly contribute to differ-
ences between groups, corrected by Benjamani-Hoch-
burg false discovery rate detection. Targeted analysis by 
qRT-PCR will validate differential abundance or expres-
sion of candidate microbial genes. Longitudinal compar-
isons will be performed within and between groups using 
multilevel simultaneous component analysis. Orthog-
onal projections to latent structures models will inte-
grate metabolomic and metagenomic data while linear 
regression, canonical correlation and hierarchal clus-
tering analysis will measure correlations between -omics 
data sets. Finally, ROC analysis will identify the ability of 
different analytes to predict long-term nutritional and 
clinical outcomes.
Immunology substudy
Integrated profiles of innate immune cell function will 
be generated for each child using principal compo-
nents analysis followed by hierarchical clustering.65 66 
This data -reduction method identifies whether absolute 
levels of specific markers or relative differences between 
markers differentiate children into groups. The resulting 
innate immune profiles will be compared between 
HIV-SAM, HIV-negative children with SAM and well-nour-
ished groups using univariable tests and multivariable 
analysis of variance of the principal components.
To address the relationship between immune func-
tion and infections, regression analyses will determine 
whether baseline innate immune profiles (or the indi-
vidual parameters defining them) are associated with 
the infectious morbidity or mortality during hospital-
isation, using logistic models for binary outcomes and 
linear models for duration. Key clinical characteristics, 
including age, sex, oedema and baseline WHZ, will 
be added to models to investigate their confounding 
effects. Multivariable stacked regression methods will 
be used to compare the impact of different factors 
on severe bacterial infections based on heterogeneity 
tests.
To determine whether treatment for SAM restores 
innate immune cell antibacterial function, mixed 
effects regression models will compare longitudinal 
changes in individual immune parameters, and the 
principal components calculated from the weights 
identified at baseline (which include well-nour-
ished controls). Similarities and differences in 
longitudinal immune profiles will be compared 
between groups using non-metric multidimensional 
scaling.65 67 68 This approach will group children 
according to their composite innate immune func-
tion, allowing the duration and variability of immune 
restoration to be evaluated over the course of nutri-
tional rehabilitation. Binary logistic regression 
will determine whether innate immune profiles at 
discharge are associated with morbidity or mortality 
during follow-up.
PAtIEnt And PubLIC InvoLvEMEnt
Patients and their caregivers were not involved in the 
design of the study. During recruitment, all caregivers 
of children admitted to hospital were given information 
about the study; those whose children had severe acute 
malnutrition were approached to give written informed 
consent. A meeting to disseminate results of the study to 
participants and their caregivers will be held at the end 
of the study. An interactive game to engage caregivers in 
the science underlying malnutrition is being developed 
in collaboration with experts from the Centre of the Cell, 
a unique science education centre based at Queen Mary 
University of London (https://www. centreofthecell. 
org/).
sAfEty rEPortIng
For all adverse events, the study team will assess expect-
edness and relatedness to study activities. Since this is an 
observational study without interventions, we anticipate 
that the risk is minimal; however, serious adverse events 
will be reported to local ethical review boards (Medical 
Research Council of Zimbabwe, and University of Zambia 
Biomedical Research Ethics Committee) and the study 
sponsor (Queen Mary University of London) according 
to their respective guidelines.
dAtA CoLLECtIon And MonItorIng
Clinical and demographic data are recorded on paper 
case report forms. All data are checked for completeness 
and plausibility before data entry and problems flagged 
for resolution by the clinical team. All data are double-en-
tered onto a dedicated password-protected online study 
database and any discrepancies resolved. Study partici-
pants are identified on electronic databases only by study 
numbers (assigned at enrolment); no personal identifiers 
are entered.
EtHICs And dIssEMInAtIon
The study complies with the principles of the Declaration 
of Helsinki (2008) and is conducted in compliance with 
the principles of Good Clinical Practice and local regu-
latory requirements in each country. Ethical approval 
was obtained from the University of Zambia Biomed-
ical Research Ethics Committee, the Joint Research 
Ethics Committee of the University of Zimbabwe and 
the Medical Research Council of Zimbabwe. The ethical 
review board of the Sponsor, Queen Mary University of 
London, provided an advisory review of the study. Since 
this is an observational study, there is no Data and Safety 
Monitoring Board.
Results will be disseminated through conference 
abstracts and peer-reviewed publications and discussed 
with relevant policymakers and programmers. Study find-
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tIME frAME And study stAtus
“Enrolment into the SAM cohorts began in July 2016 
and ended in March 2018. Enrolment of well-nourished 
controls is expected to end in March 2019. All partic-
ipants with SAM will be followed for 48 weeks, with an 
expected study completion date of March 2019.”
dIsCussIon
HOPE-SAM aims to document the short- and long-term 
clinical and nutritional outcomes of HIV-positive and 
HIV-negative children with SAM, and to identify the 
factors at presentation and at discharge from hospital 
that independently predict these outcomes. Mechanistic 
substudies aim to evaluate the contribution of enterop-
athy, microbiota, metabolome and innate immune cell 
function to these clinical outcomes. The prevalence of 
malnutrition in HIV-positive children is as high as 40% 
in some settings and the challenges of managing this 
population are well recognised.69 The WHO protocol on 
management of SAM aims to reduce case fatality below 
10%, but rates as high as 35% are still reported among 
HIV-positive children.5 70 No studies have systematically 
and longitudinally collected morbidity data in HIV-SAM, 
or documented repeat hospitalisations and mortality 
after discharge from hospital, particularly in the current 
era where ART is available on diagnosis. HOPE-SAM 
will provide a unique opportunity to enrol and follow 
a cohort of children managed for SAM in three large 
hospitals across two sub-Saharan African countries at 
several time points over a 1-year period. Nested longitu-
dinal laboratory substudies aim to better characterise the 
pathogenesis of SAM in HIV-positive and HIV-negative 
children, to determine whether pathogenic processes 
are normalised during nutritional rehabilitation and 
follow-up, and to identify potential mechanistic pathways. 
Our ultimate goal is to use the findings generated in this 
study to inform new intervention approaches that can be 
evaluated in clinical trials to improve outcomes among 
children with SAM.
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